NASDAQ · CLYM
Climb Bio, Inc.
$10.10-$0.23 (-2.23%)
Climb Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 44.9% below the high.
Loading market information…
NASDAQ · SCPH · USD
Stock price, earnings
Quote as of Oct 7, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
scPharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 9.71% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow scPharmaceuticals Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
scPharmaceuticals Inc. is a pharmaceutical firm dedicated to developing and commercializing a variety of medicinal products. Its primary investigational therapy, FUROSCIX, is a specialized formulation of furosemide delivered through an on-body infusor, intended for managing congestion in heart failure patients. The company's pipeline also encompasses scCeftriaxone, an antibiotic aimed at treating infections caused by both gram-positive and gram-negative bacteria, as well as the scCarbapenem program, another antibiotic designed for gram-negative bacterial infections. Additionally, scPharmaceuticals has entered into a collaboration agreement with West Pharmaceutical Services, Inc. for the advancement of a single-use SmartDose device. Founded in 2013, the company's main operations are based in Burlington, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:07 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2024 | May 14, 2024 | -$0.36+20.0% vs estimate | $6.10M+2.04% vs estimate |
|---|
| Q4 2023 | Mar 13, 2024 | -$0.35+16.67% vs estimate | $6.10M+10.43% vs estimate |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.10-$0.23 (-2.23%)
Climb Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 44.9% below the high.
$16.70+$0.05 (+0.3%)
Orchard Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
$8.05$0.00 (0.0%)
Vigil Neuroscience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.62% below the high.
$4.26$0.00 (0.0%)
Checkpoint Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.33% below the high.
$5.00$0.00 (0.0%)
2seventy bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.66% below the high.
$4.00+$0.01 (+0.25%)
Inozyme Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 35.9% below the high.
$5.38-$0.01 (-0.09%)
Third Harmonic Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.42% below the high.
$0.60-$0.02 (-2.47%)
Standard BioTools Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.84% below the high.
